Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

NCT03920839 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03920839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03920839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Withdrawn
Start date
July 15, 2019
Completion date
November 4, 2019
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and/or metastatic solid tumors, advanced/metastatic unresectable malignant pleural mesothelioma, stage iiib not amenable to curative therapy to stage iv non-small cell lung cancer